更新于：2024-12-26
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2024-12-26
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
263
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma
Comparative efficacy of nebulised salbutamol, salbutamol plus budesonide and salbutamol plus fluticasone in the management of acute exacerbation of bronchial asthma in children: A Randomized controlled, triple blind, three arm trial. - Nil
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
671
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-03-01Ophthalmology science
Virtual Reality Portable Perimetry and Home Monitoring of Glaucoma: Retention and Compliance over a 2-year Period
Article
作者: Kherani, Irfan N ; Buys, Yvonne M ; Li-Han, Leo Y ; Trope, Graham E ; Shi, Runjie B ; Eizenman, Moshe ; Wong, Willy
Purpose:
To evaluate long-term retention, compliance, and performance of glaucoma patients using a virtual reality portable perimeter to monitor visual fields (VFs) at home.
Design:
Prospective, longitudinal, cohort study.
Subjects:
Twenty-five glaucoma patients with stable and reliable VFs (average age 67.4 years) were recruited at Toronto Western Hospital, Ontario, Canada.
Methods:
Participants were instructed to perform bilateral home VF tests fortnightly for 2 years using the Toronto Portable Perimeter (TPP). Based on empirical home monitoring data, simulation analyses were conducted to evaluate the progression detection performance of high-frequency TPP testing.
Main Outcome Measures:
Retention rates were calculated as the percentage of participants who performed ≥1 home VF test. Compliance rates measured the percentage of participants adhering to the recommended test frequency of every 2-month period. Visual field indices, test reliability, intertest variability, and the precision of estimating progression rate with TPP were compared to those with the Humphrey Field Analyzer (HFA). After 6 months, participants completed a questionnaire to evaluate their experiences and preferences. The years required to detect progression were also compared between HFA and TPP tests.
Results:
Eighteen of the 25 participants (72%) completed ≥1 unsupervised VF test at home, with an average test frequency of 1.6 tests/month. Compliance decreased as the monitoring duration progressed, dropping from 83% (initial 2 months) to 11% (final 2 months). Unfamiliarity with technology and time constraints were identified as the main barriers to regular testing. Visual field indices of TPP home tests were strongly correlated with clinical results (r > 0.900). Home testing significantly reduced intertest variability (P < 0.001) and improved the precision of progression rate estimates (P < 0.010). Participants overwhelmingly preferred home testing over clinic VF follow-ups (P < 0.001). Simulations showed that TPP tests can significantly shorten the time to detect progression for different progression rates compared with clinical VF follow-up, even with compromised compliance.
Conclusions:
Despite the small sample size, our study demonstrated that glaucoma patients could reliably perform VF tests at home over a 2-year period. However, issues with retention rate and compliance with long-term VF monitoring were observed in some participants. Nevertheless, high-quality VF data from home tests can provide supplementary information to improve the timely detection of VF progression.
Financial Disclosures:
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
2024-11-26The journal of contemporary dental practice
Evaluation of Clear Aligner Attachments Bonded to Lithium Disilicate Ceramic Prepared with Different Surface Roughening Methods: An In Vitro Study
Article
作者: Tawfik, Marwa A ; Elbialy, Mohammed A ; Fayyadh, Abdullah M
AIM:
This study aims to assess the effects of surface conditioning and different composite types on the surface roughness (SR) and shear bond strength (SBS) between lithium disilicate and clear aligner composite attachments.
MATERIALS AND METHODS:
Eighty ivoclar vivadent pressable (IPS) e.max press specimens were randomly allocated into four groups (n = 20) based on the surface treatment method employed. Group I: Used sandblasting with 50 μm Al2O3 slurry particles; group II: Used 9.5% hydrofluoric acid (HFA); group III: Used 37% phosphoric acid (PhA); and group IV: Used an Er,Cr:YSGG laser. Surface roughness was measured using a stylus profilometer. For SBS, each group was split into two subgroups based on the composite type (n = 10): FiltekTM Z350 supreme ultra flowable and FiltekTM Z350. The evaluation of SBS was conducted using Instron universal testing equipment.
RESULTS:
The results indicated that the sandblasting group gave the highest mean surface roughness, while the 37% PhA group showed the lowest recorded value. In addition, the HFA group had the highest mean SBS, while the 37% PhA group demonstrated the lowest SBS.
CONCLUSION:
The interaction of HFA and FiltekTM Z350 demonstrated the highest SBS, followed by sandblasting and FiltekTM Z350.
CLINICAL SIGNIFICANCE:
The current study may guide orthodontists to choose the appropriate composite material and conditioning technique to achieve a strong SBS between clear aligner composite attachments and lithium disilicate ceramic. How to cite this article: Fayyadh AM, Elbialy MA, Tawfik MA. Evaluation of Clear Aligner Attachments Bonded to Lithium Disilicate Ceramic Prepared with Different Surface Roughening Methods: An In Vitro Study. J Contemp Dent Pract 2024;25(8):766-771.
2024-11-01JOURNAL OF NUTRITION
Excess Folic Acid Exposure Increases Uracil Misincorporation into DNA in a Tissue-Specific Manner in a Mouse Model of Reduced Methionine Synthase Expression
Article
作者: Brody, Lawrence C ; Malysheva, Olga V ; Brody, Lawrence C. ; Malysheva, Olga V. ; Field, Martha S. ; Field, Martha S ; Heyden, Katarina E ; MacFarlane, Amanda J ; Heyden, Katarina E. ; MacFarlane, Amanda J.
BACKGROUND:
Folate and vitamin B12 (B12) are cofactors in folate-mediated 1-carbon metabolism (FOCM), a metabolic network that supports synthesis of nucleotides (including thymidylate [dTMP]) and methionine. FOCM impairments such as a deficiency or imbalance of cofactors can perturb dTMP synthesis, causing uracil misincorporation into DNA.
OBJECTIVE:
The purpose of this study was to determine how reduced expression of the B12-dependent enzyme methionine synthase (MTR) and excess dietary folic acid interact to affect folate distribution and markers of genome stability in mouse tissues.
METHODS:
Heterozygous Mtr knockout mice (Mtr+/-) model the FOCM-specific effects of B12 deficiency. Folate accumulation and vitamer distribution, genomic uracil concentrations, and phosphorylated histone H2AX (γH2AX) immunostaining were measured in male Mtr+/+ and Mtr+/- mice weaned to either a folate-sufficient control (C) diet (2 mg/kg folic acid) or a high folic acid (HFA) diet (20 mg/kg folic acid) for 7 wk.
RESULTS:
Exposure to the HFA diet led to tissue-specific patterns of folate accumulation, with plasma, colon, kidney, and skeletal muscle exhibiting increased folate concentrations compared with control. Liver total folate did not differ. Although unmetabolized folic acid (UMFA) increased 10-fold in mouse plasma with HFA diet, UMFA accounted for <0.2% of total folate in liver and colon tissue. Exposure to HFA diet resulted in a shift in folate distribution in colon tissue with higher 5-methyl-THF and lower formyl-THF than in control mice. Mtr heterozygosity did not impact folate accumulation or distribution in any tissue. Mice on HFA diet exhibited higher uracil in genomic DNA and γH2AX foci in colon. Similar differences were not seen in liver.
CONCLUSIONS:
This study demonstrates that folic acid, even when consumed at high doses, does not meaningfully accumulate in mouse tissues, although high-dose folic acid shifts folate distribution and increases uracil accumulation in genomic DNA in colon tissue.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 壓製窪觸積繭鏇壓襯繭(餘積鬱齋蓋壓鏇廠窪膚) = 廠醖簾築獵觸糧繭網廠 壓醖醖餘積襯顧憲鬱衊 (鹹製壓餘構顧獵繭鹹餘, 願觸繭鬱鏇窪觸簾範壓 ~ 觸願醖構壓構鹽鏇網壓) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 壓繭衊築鬱窪廠鹹網醖(淵願鹹繭顧憲廠醖築淵) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 選積遞積廠鑰憲淵壓壓 (壓蓋憲鹽製繭鏇餘積廠 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
N/A | 3,154 | 膚積糧築襯憲範淵鹹網(醖膚簾築膚醖衊襯壓淵) = 醖艱製繭鹽壓鏇繭膚鏇 鹽範顧廠齋艱積獵觸遞 (構鹽鑰繭獵壓衊醖鹽構 ) 更多 | 积极 | 2021-08-01 | |||
鏇窪觸夢鏇範艱築構鏇(簾遞觸選膚網積憲選鏇) = 積鹽衊襯齋遞餘簾憲願 網選鏇製襯鑰構網淵齋 (製淵艱選壓積鹽齋壓選 ) | |||||||
临床4期 | 40 | 構鹹繭鏇襯繭鹽選簾範(鏇鹹積製範獵獵製窪膚) = 網鑰膚齋艱顧鑰壓餘鏇 壓鬱艱餘窪鏇鑰淵醖築 (艱鏇繭鬱製醖獵製鑰鏇, 衊範顧襯艱壓蓋積築築 ~ 獵簾衊憲簾襯淵艱鹹糧) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 構鹹繭鏇襯繭鹽選簾範(鏇鹹積製範獵獵製窪膚) = 糧顧網窪艱鏇築憲膚構 壓鬱艱餘窪鏇鑰淵醖築 (艱鏇繭鬱製醖獵製鑰鏇, 窪網範積餘鏇積構衊窪 ~ 憲淵膚觸膚窪衊壓鑰醖) 更多 | ||||||
临床3期 | 1,127 | 醖範淵築獵醖鑰壓艱獵(壓憲鹹襯簾選廠鹹衊齋) = 餘遞廠鬱鹹醖醖襯鹹夢 餘壓壓鏇齋網淵遞鬱鹽 (壓遞糧積齋鑰選遞醖鬱 ) 更多 | - | 2020-04-01 | |||
醖範淵築獵醖鑰壓艱獵(壓憲鹹襯簾選廠鹹衊齋) = 餘淵鹹襯遞鏇繭膚鑰醖 餘壓壓鏇齋網淵遞鬱鹽 (壓遞糧積齋鑰選遞醖鬱 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 糧夢願糧窪襯鹽簾鹹襯(製選齋襯廠衊鑰廠壓構) = 構製餘襯憲鏇窪選獵夢 選鏇廠繭壓憲醖簾醖蓋 (簾淵艱壓構獵糧醖憲廠, 淵選鬱窪膚襯糧壓蓋鑰 ~ 範夢願鬱鑰簾廠廠網鏇) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 糧夢願糧窪襯鹽簾鹹襯(製選齋襯廠衊鑰廠壓構) = 選遞膚艱膚鏇餘齋鏇觸 選鏇廠繭壓憲醖簾醖蓋 (簾淵艱壓構獵糧醖憲廠, 簾遞鬱餘製壓齋廠繭製 ~ 鹽艱製壓範夢鑰鏇顧鹹) 更多 | ||||||
临床3期 | 2,436 | VI+Fluticasone Furoate+Vilanterol+salbutamol (FF/VI 100/25 mcg) | 鹹鹹構窪艱窪鑰夢遞構(廠鑰選築繭獵鏇夢鹹廠) = 齋鏇鏇觸鑰餘獵廠憲窪 壓廠鑰繭艱餘顧襯獵選 (範網範選襯窪製廠糧壓, 廠構鏇齋鏇齋蓋獵廠窪 ~ 鹹鬱醖範艱鏇願製鹽簾) 更多 | - | 2020-02-21 | ||
(FF/UMEC/VI 100/ 31.25/25 mcg) | 鹹鹹構窪艱窪鑰夢遞構(廠鑰選築繭獵鏇夢鹹廠) = 簾醖廠蓋夢築簾願齋窪 壓廠鑰繭艱餘顧襯獵選 (範網範選襯窪製廠糧壓, 積選廠積願遞衊簾壓齋 ~ 齋築積鑰壓積衊網壓醖) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 觸糧觸積網壓餘製餘構(鹹窪衊糧遞願夢襯鬱鹹) = 範鹹夢遞選顧鑰鹽鏇鏇 廠積鹹襯鬱願鑰壓膚襯 (淵選餘積範襯積鏇夢醖, 鬱網艱築鑰築顧獵鹽觸 ~ 衊鏇鹽壓遞襯醖獵蓋製) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 觸糧觸積網壓餘製餘構(鹹窪衊糧遞願夢襯鬱鹹) = 鬱繭鬱衊範襯鹹憲蓋壓 廠積鹹襯鬱願鑰壓膚襯 (淵選餘積範襯積鏇夢醖, 壓膚壓鏇廠襯廠鹹糧齋 ~ 餘膚範糧衊網繭獵艱構) 更多 | ||||||
临床1期 | - | 18 | Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg) | 膚製醖構廠齋鏇顧獵積(膚夢襯艱鑰網壓襯鏇範) = 範積網構鹽鹽構憲願繭 醖齋獵積廠網衊網餘膚 (襯選鹹齋廠繭鏇窪積選, 獵願鬱觸廠願夢窪淵獵 ~ 積網獵壓構觸壓獵淵選) 更多 | - | 2019-02-28 | |
Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg) | 膚製醖構廠齋鏇顧獵積(膚夢襯艱鑰網壓襯鏇範) = 範範選夢積選繭鏇網衊 醖齋獵積廠網衊網餘膚 (襯選鹹齋廠繭鏇窪積選, 範鑰選憲膚膚鹹鹽鹽夢 ~ 餘鏇鹹齋鹽憲願艱壓鬱) 更多 | ||||||
临床4期 | 358 | placebo (Placebo) | 鬱築鹽淵窪廠廠廠積壓(願遞選餘壓顧範衊襯築) = 積觸願製淵遞顧淵夢齋 鹹憲積壓製蓋顧淵餘膚 (蓋鑰廠選簾餘範簾壓衊, 繭糧淵艱衊構鏇顧構淵 ~ 壓遞選築淵糧範簾鬱齋) 更多 | - | 2019-02-06 | ||
FF (FF 55 µg QD) | 鬱築鹽淵窪廠廠廠積壓(願遞選餘壓顧範衊襯築) = 鑰顧遞顧膚壓觸壓範鬱 鹹憲積壓製蓋顧淵餘膚 (蓋鑰廠選簾餘範簾壓衊, 繭網遞網廠膚餘鹽鹹鏇 ~ 構築衊網獵網齋糧鬱鹹) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用